CDMO

#CDMO #Lonza #Manufacturing #Merck #Mergers and acquisitions

Lonza signs agreement to acquire US CDMO network from Merck

Lonza has signed a definitive agreement to acquire five CDMO manufacturing sites in the US from Merck (Darmstadt, Germany) at a total enterprise valuation in the low- to mid-triple-digit millions Swiss francs. The acquisition expands Lonza’s US CDMO manufacturing footprint from four to nine sites and complements its global network… Read More

#News

#Cambrex #CDMO #New facility #R&D facility #Research and development

Cambrex builds new $30 million R&D facility

CDMO Cambrex has begun construction on a new R&D facility in Milan, Italy, a $30 million investment will add advanced analytical development and process R&D capabilities, alongside upgrades to multiple production plants. The Milan R&D expansion is expected to be completed in the second half of 2027. To accommodate future… Read More

#Business & Investment #News

Scientist using a laptop
#Biotech #CDMO #Clinical trial

Biotech reliance on large CDMOs could cause overruns of 40% 

Overreliance of biotechs on large CDMOs could cause overruns of up to 40%, an industry expert has warned.  Madhav Bhutada, Director of Shilpa Biologicals, urged biotechs to take a broader and earlier approach to CDMO selection as funding conditions improve across the sector.   Bhutada said many emerging biopharma innovators –… Read More

#News

#CDMO #Japan

Japanese pharma shifting earlier to CDMOs, report says 

Japanese pharma companies are shifting to earlier CDMO outsourcing, Neuland Laboratories has said.  According to the report, pharma companies are engaging contract development and manufacturing organisations (CDMOs) earlier in the development cycle, as increasing complexity in peptide programmes places greater strain on in-house capabilities.  This… Read More

#News

MRI of the brain
#CDMO #epilepsy #Neurology

Neumirna and ten23 partner to advance epilepsy treatments

Biotechnology company Neumirna Therapeutics has announced its partnership with CDMO company ten23 health to advance treatments for epilepsy and other neurological diseases.  The companies will collaborate to advance NMT.001, a microRNA–targeting antisense oligonucleotide (ASO) designed to treat drug-resistant epilepsy, towards clinical development. The goal is to bring… Read More

#News

#Biotech #CDMO #Collaboration #Drug development

How speed and clarity decide biotech’s winners 

Dr Thomas Meins, General Manager of WuXi AppTec’s subsidiary Crelux in Munich, Germany discusses how agile collaboration helps innovators adapt and succeed. Every biotech project begins with a vision, an idea with the potential to turn science into impact. But a vision alone is not enough. Turning that idea… Read More

#Exclusive Content

Stem cells
#CDMO #Clinical trials #Drug delivery #EXO Biologics #Exosomes #ExoXpert #Mesenchymal stem cells

CDMO launched to service increasing demand for exosomes 

EXO Biologics has launched ExoXpert, a contract development and manufacturing organisation (CDMO) specialising in exosomes which offers a mesenchymal stem cells (MSC)-based exosome manufacturing platform used in European clinical trials.  During the development of its lead exosome candidate, EXOB-001, Exo Biologics developed ExoPulse, an industrial exosome manufacturing… Read More

#News

#CDMO #Collaboration #CRO #Drug development #Drug discovery #Guide

Latest Guide: Streamline your drug development pathway

In pharmaceutical development, collaborating with multiple Contract Development and Manufacturing Organisations (CDMOs) and Contract Research Organisations (CROs) poses potential hurdles – from poor communication to delays, errors, and inconsistent feedback during the progression from preclinical to formulation optimisation and clinical trials. Download this new guide from SGS… Read More

#News

#CDMO #Collaboration #CRO #Drug development #Drug discovery #Guide

Streamline your drug development pathway

In pharmaceutical development, collaborating with multiple Contract Development and Manufacturing Organisations (CDMOs) and Contract Research Organisations (CROs) poses potential hurdles – from poor communication to delays, errors, and inconsistent feedback during the progression from preclinical to formulation optimisation and clinical trials. Download this SGS guide to discover: How to collaborate… Read More

#Intelligence #Resources

Cell and gene therapy
#CDMO #Cell and gene therapy #eBook #Gene therapy #Manufacturing

eBook: Analytical methods for viral vector development in gene therapy

The eleventh eBook of the Hamilton series ‘Analytical Methods for Viral Vector Development and Manufacturing in Gene Therapy’ is now available. Download the eBook to learn about: Gene therapy: history, viral vectors and the role of CDMOs Automation of analytical assays during viral vector development and manufacturing… Read More

#News

#CDMO #Cell and gene therapy #Gene therapy #Manufacturing

Analytical methods for viral vector development and manufacturing in gene therapy

In the eleventh eBook of the Hamilton series ‘Analytical Methods for Viral Vector Development and Manufacturing in Gene Therapy’, we learn about: Gene therapy: history, viral vectors and the role of CDMOs Automation of analytical assays during viral vector development and manufacturing The solutions that Hamilton offers to customers working… Read More

#Resources

#Acquisition #Biopharma #Biotechnology #CDMO #Cell and gene therapy #Cold chain #Drug development #GSK #Pfizer #Regulatory #Supply chain

New podcast: A business case for drug discovery

This is the latest episode of the free DDW narrated podcast, “A business case for drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “A deal in the making”, “Why project management… Read More

#News

Applause
#Biotherapeutics #CDMO #Manufacturing

SGS Quay Pharma receives UK enterprise award 

Pharmaceutical contract development and manufacturing organisation (CDMO) SGS Quay Pharma has been recognised with a Queen’s Award in the UK for the strength of its export sales.   The CDMO won a Queen’s Award for Enterprise in the category of International Trade and was recognised for the… Read More

#News

#Biopharma #Biotechnology #CDMO #Drug development

Why project management holds the key to efficient drug development

Listen to this article on the DDW Podcast: Ian Hollingsworth, Associate Director of product development at Boyds, the global drug development consultancy, explains the benefits to the drug development lifecycle of building strong partnerships with external consultants, and when and how to get the best from them. Everyone can… Read More

#Exclusive Content

Peptide
#CDMO #Manufacturing #Oligonucleotides

Cell-penetrating peptides as a delivery system for oligonucleotides

CDMO in peptides and oligonucleotides manufacturing, Bachem, has started building a new future for oligonucleotides: solving the industry’s main challenges around capacity, sustainability and cost-effectiveness. Emerging as a new treatment option in rare and orphan disease areas, oligonucleotide therapeutics have matured into a drug class with a broad indication spectrum. Read More

#Exclusive Content #Opinion